RESUMO
OBJECTIVE: Bariatric surgical procedures are being commonly performed increasingly, and many surgical candidates are concomitantly taking psychotropic medication. This paper aims to elucidate issues when prescribing psychiatric medication in this setting of substantial anatomical and physiological change. METHOD: A hand search of the literature to assess the current understanding of effects of various bariatric procedures on the bioavailability of psychotropic medication. RESULTS: Predominantly malabsorptive bariatric procedures may reduce bioavailability of some but not all commonly used psychiatric medications. There is minimal information about the effects of the most commonly performed surgery, vertical sleeve gastrectomy. Lithium prescription and monitoring requires caution. CONCLUSIONS: There is limited guidance for prescription for psychotropic medication in the bariatric surgery patient group, and vigilance for unexpected adverse effects or altered efficacy is warranted.
Assuntos
Cirurgia Bariátrica/métodos , Prescrições de Medicamentos/estatística & dados numéricos , Transtornos Mentais/tratamento farmacológico , Obesidade Mórbida/cirurgia , Padrões de Prática Médica/estatística & dados numéricos , Medicamentos sob Prescrição , Psicotrópicos , Gastrectomia , Humanos , Transtornos Mentais/complicações , Obesidade Mórbida/complicações , Cuidados Pós-Operatórios , Medicamentos sob Prescrição/farmacocinética , Medicamentos sob Prescrição/uso terapêutico , Psicotrópicos/farmacocinética , Psicotrópicos/uso terapêutico , Resultado do Tratamento , Redução de PesoRESUMO
A multitude of pharmacokinetics studies have been published. However, due to the lack of an open database, pharmacokinetics data, as well as the corresponding meta-information, have been difficult to access. We present PK-DB (https://pk-db.com), an open database for pharmacokinetics information from clinical trials. PK-DB provides curated information on (i) characteristics of studied patient cohorts and subjects (e.g. age, bodyweight, smoking status, genetic variants); (ii) applied interventions (e.g. dosing, substance, route of application); (iii) pharmacokinetic parameters (e.g. clearance, half-life, area under the curve) and (iv) measured pharmacokinetic time-courses. Key features are the representation of experimental errors, the normalization of measurement units, annotation of information to biological ontologies, calculation of pharmacokinetic parameters from concentration-time profiles, a workflow for collaborative data curation, strong validation rules on the data, computational access via a REST API as well as human access via a web interface. PK-DB enables meta-analysis based on data from multiple studies and data integration with computational models. A special focus lies on meta-data relevant for individualized and stratified computational modeling with methods like physiologically based pharmacokinetic (PBPK), pharmacokinetic/pharmacodynamic (PK/PD), or population pharmacokinetic (pop PK) modeling.
Assuntos
Bases de Dados Factuais , Modelos Estatísticos , Anotação de Sequência Molecular , Medicamentos sob Prescrição/farmacocinética , Área Sob a Curva , Peso Corporal , Cafeína/farmacocinética , Ensaios Clínicos como Assunto , Anticoncepcionais Orais/administração & dosagem , Relação Dose-Resposta a Droga , Vias de Administração de Medicamentos , Esquema de Medicação , Cálculos da Dosagem de Medicamento , Ontologia Genética , Meia-Vida , Humanos , Fumar/fisiopatologiaRESUMO
Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.
Assuntos
Infecções por Coronavirus/tratamento farmacológico , Pneumonia Viral/tratamento farmacológico , Medicamentos sob Prescrição/farmacologia , Analgésicos/farmacologia , Antiasmáticos/farmacologia , Antibacterianos/farmacologia , Anti-Inflamatórios/farmacologia , Anticoagulantes/farmacologia , Antineoplásicos/farmacologia , Antituberculosos/farmacologia , Antivirais/farmacologia , Betacoronavirus , COVID-19 , Fármacos Cardiovasculares/farmacologia , Interações Medicamentosas , Humanos , Hidroxicloroquina/farmacologia , Hipoglicemiantes/farmacologia , Hipolipemiantes/farmacologia , Interferon beta-1b/farmacologia , Pandemias , Medicamentos sob Prescrição/farmacocinética , Psicotrópicos/farmacologia , Receptores de Interleucina/antagonistas & inibidores , Medição de Risco , SARS-CoV-2 , Hormônios Tireóideos/farmacologia , Tratamento Farmacológico da COVID-19RESUMO
Adverse pharmacokinetic interactions between illicit substances and clinical drugs are of a significant health concern. Illicit substances are taken by healthy individuals as well as by patients with medical conditions such as mental illnesses, acquired immunodeficiency syndrome, diabetes mellitus and cancer. Many individuals that use illicit substances simultaneously take clinical drugs meant for targeted treatment. This concomitant usage can lead to life-threatening pharmacokinetic interactions between illicit substances and clinical drugs. Optimal levels and activity of drug-metabolizing enzymes and drug-transporters are crucial for metabolism and disposition of illicit substances as well as clinical drugs. However, both illicit substances and clinical drugs can induce changes in the expression and/or activity of drug-metabolizing enzymes and drug-transporters. Consequently, with concomitant usage, illicit substances can adversely influence the therapeutic outcome of coadministered clinical drugs. Likewise, clinical drugs can adversely affect the response of coadministered illicit substances. While the interactions between illicit substances and clinical drugs pose a tremendous health and financial burden, they lack a similar level of attention as drug-drug, food-drug, supplement-drug, herb-drug, disease-drug, or other substance-drug interactions such as alcohol-drug and tobacco-drug interactions. This review highlights the clinical pharmacokinetic interactions between clinical drugs and commonly used illicit substances such as cannabis, cocaine and 3, 4-Methylenedioxymethamphetamine (MDMA). Rigorous efforts are warranted to further understand the underlying mechanisms responsible for these clinical pharmacokinetic interactions. It is also critical to extend the awareness of the life-threatening adverse interactions to both health care professionals and patients.
Assuntos
Drogas Ilícitas/farmacocinética , Medicamentos sob Prescrição/farmacocinética , Animais , Interações Medicamentosas , Humanos , Drogas Ilícitas/efeitos adversos , Drogas Ilícitas/farmacologia , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacologia , Transtornos Relacionados ao Uso de Substâncias/metabolismoRESUMO
Bariatric surgery has been on the rise and patients often have multiple indications for pre- and post-operative pharmacotherapy. Procedures target the stomach and/or small intestine and affect weight loss through restriction, malabsorption, or a combination of the two. The absorption and/or metabolism of drugs via the gastrointestinal tract could be altered by different mechanisms. Several cases at the North Carolina Office of the Chief Medical Examiner's Toxicology Laboratory (NCOCME) have raised questions about the potential impact of these procedures on the disposition of drugs in the body and how that altered disposition may affect cause and manner of death. Overmedication and postmortem redistribution are not enough to explain the phenomena seen in some NCOCME bariatric surgery-related casework. Case examples include a 46-year-old female with a history of Roux-en-Y gastric bypass (RYGB) who suffered a witnessed collapse. Toxicological findings included elevated concentrations of oxymorphone at 0.49 mg/L in vena cava blood. A 67-year-old female, who died from vomiting and bacterial gastritis one day after placement of two intragastric weight-loss balloons, had elevated concentrations of duloxetine at 1.4 mg/L in the iliac vein blood and 9.3 mg/kg in the liver. Her medication was strictly controlled by her sister and gastric contents were without intact tablets or residue at autopsy.
Assuntos
Cirurgia Bariátrica , Toxicologia Forense , Absorção Gástrica , Absorção Intestinal , Medicamentos sob Prescrição/farmacocinética , Estômago/cirurgia , Autopsia , Cirurgia Bariátrica/métodos , Derivação Gástrica/métodos , Humanos , Obesidade Mórbida/cirurgia , Medicamentos sob Prescrição/administração & dosagem , Medicamentos sob Prescrição/efeitos adversos , Redução de PesoAssuntos
Desenvolvimento de Medicamentos/organização & administração , Medicamentos sob Prescrição/farmacologia , Medicamentos sob Prescrição/uso terapêutico , United States Food and Drug Administration/organização & administração , Avaliação Pré-Clínica de Medicamentos/métodos , Determinação de Ponto Final , Humanos , Modelos Estatísticos , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinética , Vigilância de Produtos Comercializados , Projetos de Pesquisa , Estados UnidosRESUMO
BACKGROUND: Enzyme-mediated biotransformation of pharmacological agents is a crucial step in xenobiotic detoxification and drug disposition. Herein, we investigated the metabolism and physicochemical properties of the top 200 most prescribed drugs (established) as well as drugs approved by the US Food and Drug Administration (FDA) between 2005 and 2016 (newly approved). OBJECTIVE: Our objective was to capture the changing trends in the routes of administration, physicochemical properties, and prodrug medications, as well as the contributions of drug-metabolizing enzymes and transporters to drug clearance. METHODS: The University of Washington Drug Interaction Database (DIDB®) as well as other online resources (e.g., CenterWatch.com, Drugs.com, DrugBank.ca, and PubChem.ncbi.nlm.nih.gov) was used to collect and stratify the dataset required for exploring the above-mentioned trends. RESULTS: Analyses revealed that ~ 90% of all drugs in the established and newly approved drug lists were administered systemically (oral or intravenous). Meanwhile, the portion of biologics (molecular weight > 1 kDa) was 15 times greater in the newly approved list than established drugs. Additionally, there was a 4.5-fold increase in the number of compounds with a high calculated partition coefficient (cLogP > 3) and a high total polar surface area (> 75 Å2) in the newly approved drug vs. the established category. Further, prodrugs in established or newly approved lists were found to be converted to active compounds via hydrolysis, demethylases, and kinases. The contribution of cytochrome P450 (CYP) 3A4, as the major biotransformation pathway, has increased from 40% in the established drug list to 64% in the newly approved drug list. Moreover, the role of CYP1A2, CYP2C19, and CYP2D6 were decreased as major metabolizing enzymes among the newly approved medications. Among non-CYP major metabolizers, the contribution of alcohol dehydrogenases/aldehyde dehydrogenases (ADH/ALDH) and sulfotransferases decreased in the newly approved drugs compared with the established list. Furthermore, the highest contribution among uptake and efflux transporters was found for Organic Anion Transporting Polypeptide 1B1 (OATP1B1) and P-glycoprotein (P-gp), respectively. CONCLUSIONS: The higher portion of biologics in the newly approved drugs compared with the established list confirmed the growing demands for protein- and antibody-based therapies. Moreover, the larger number of hydrophilic drugs found in the newly approved list suggests that the probability of toxicity is likely to decrease. With regard to CYP-mediated major metabolism, CYP3A5 showed an increased involvement owing to the identification of unique probe substrates to differentiate CYP3As. Furthermore, the contribution of OATP1B1 and P-gp did not show a significant shift in the newly approved drugs as compared to the established list because of their broad substrate specificity.
Assuntos
Aprovação de Drogas , Medicamentos sob Prescrição , Animais , Transporte Biológico , Biotransformação , Humanos , Medicamentos sob Prescrição/administração & dosagem , Medicamentos sob Prescrição/química , Medicamentos sob Prescrição/farmacocinética , Estados Unidos , United States Food and Drug AdministrationRESUMO
In silico network-based methods have shown promising results in the field of drug development. Yet, most of networks used in the previous research have not included context information even though biological associations actually do appear in the specific contexts. Here, we reconstruct an anatomical context-specific network by assigning contexts to biological associations using protein expression data and scientific literature. Furthermore, we employ the context-specific network for the analysis of drug effects with a proximity measure between drug targets and diseases. Distinct from previous context-specific networks, intercellular associations and phenomic level entities such as biological processes are included in our network to represent the human body. It is observed that performances in inferring drug-disease associations are increased by adding context information and phenomic level entities. In particular, hypertension, a disease related to multiple organs and associated with several phenomic level entities, is analyzed in detail to investigate how our network facilitates the inference of drug-disease associations. Our results indicate that the inclusion of context information, intercellular associations, and phenomic level entities can contribute towards a better prediction of drug-disease associations and provide detailed insight into understanding of how drugs affect diseases in the human body.
Assuntos
Algoritmos , Biologia Computacional/métodos , Drogas em Investigação/farmacocinética , Medicamentos sob Prescrição/farmacocinética , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/patologia , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/genética , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/patologia , Doenças do Tecido Conjuntivo/tratamento farmacológico , Doenças do Tecido Conjuntivo/genética , Doenças do Tecido Conjuntivo/metabolismo , Doenças do Tecido Conjuntivo/patologia , Doenças do Sistema Digestório/tratamento farmacológico , Doenças do Sistema Digestório/genética , Doenças do Sistema Digestório/metabolismo , Doenças do Sistema Digestório/patologia , Doenças Hematológicas/tratamento farmacológico , Doenças Hematológicas/genética , Doenças Hematológicas/metabolismo , Doenças Hematológicas/patologia , Humanos , Rim/efeitos dos fármacos , Rim/metabolismo , Rim/patologia , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Pulmão/patologia , Doenças Metabólicas/tratamento farmacológico , Doenças Metabólicas/genética , Doenças Metabólicas/metabolismo , Doenças Metabólicas/patologia , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Doenças Musculoesqueléticas/tratamento farmacológico , Doenças Musculoesqueléticas/genética , Doenças Musculoesqueléticas/metabolismo , Doenças Musculoesqueléticas/patologia , Miocárdio/metabolismo , Miocárdio/patologia , Neoplasias/tratamento farmacológico , Neoplasias/genética , Neoplasias/metabolismo , Neoplasias/patologia , Doenças do Sistema Nervoso/tratamento farmacológico , Doenças do Sistema Nervoso/genética , Doenças do Sistema Nervoso/metabolismo , Doenças do Sistema Nervoso/patologiaRESUMO
Abstract Since the enforcement of Generics Act (1999), three types of pharmaceutically equivalent products are marketed in Brazil: innovative reference (REF), "similar" (S) and generic (G) drugs. The S (brand name) and G (generic name) borrow from REF (brand name) clinical data on safety and efficacy and dosage regimen. G (but not S) is bioequivalent to and interchangeable with REF. Starting in 2003, Brazilian Sanitary Surveillance Agency (Anvisa) has required data on relative bioavailability tests (with REF) to approve (or renew registration of) S drugs. In 2014, Anvisa extended interchangeability notion to similar drugs with a "comparable" bioavailability, i.e., an "equivalent" similar drug (EQ). Drugs for chronic diseases and "critical dose medicines" are listed among the EQ drugs approved. Interchangeability of nonbioequivalent medicines raises deep concerns regarding therapeutic failures and adverse events. Concerns are even more worrisome if patients switch from one drug to another during an ongoing treatment for illnesses such as epilepsy, congestive heart failure, hypertension, diabetes and/or substitutable drugs have a narrow therapeutic index.
Resumo A partir da vigência da lei dos genéricos (1999), três tipos de produtos farmaceuticamente equivalentes são comercializados no Brasil: o medicamento inovador de refência (REF), o produto "similar" (S), e o genérico (G). O similar (nome de fantasia) e o genérico (nome genérico) tomam de empréstimo do REF (nome de fantasia) os dados clínicos de segurança e eficácia e a posologia. G (mas não S) é bioequivalente ao, e intercambiável com REF. Desde 2003, a Agência Nacional de Vigilância Sanitária (Anvisa) exige dados de testes de biodisponibilidade relativa para registrar (ou renovar o registro de) medicamentos S. Em 2014, a Anvisa estendeu o conceito de intercambialidade aos medicamentos similares com biodisponibilidade "comparável", i.e., um medicamento similar "equivalente" (EQ). Medicamentos para doenças crônicas e "fármacos de dose crítica" estão listados entre os produtos EQ aprovados. A intercambialidade de medicamentos não-bioequivalentes suscita grande preocupação quanto a falhas terapêuticas e eventos adversos. Os receios são ainda maiores se os pacientes trocam um medicamento por outro durante o tratamento de doenças como epilepsia, insuficiência cardíaca, hipertensão, diabetes e/ou os produtos farmacêuticos substituídos tem um índice terapêutico estreito.
Assuntos
Humanos , Medicamentos Genéricos/administração & dosagem , Medicamentos sob Prescrição/administração & dosagem , Substituição de Medicamentos/métodos , Legislação de Medicamentos , Brasil , Disponibilidade Biológica , Equivalência Terapêutica , Medicamentos Genéricos/efeitos adversos , Medicamentos Genéricos/farmacocinética , Falha de Tratamento , Aprovação de Drogas/legislação & jurisprudência , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinética , Substituição de Medicamentos/efeitos adversos , Segurança do Paciente , Índice TerapêuticoRESUMO
The use of prescribed and over-the-counter medications in pregnancy is on the rise. Many women become pregnant at an older age and with preexisting medical conditions that require pharmacotherapy. In addition, pregnancy is associated with profound changes in the physiology of virtually every organ in the body, which affect medications' pharmacokinetics and pharmacodynamics. Despite all of these, pregnant women are still considered therapeutic orphans, as the majority of current therapeutics were never studied in pregnancy. The goals of this review are to synthesize the available information regarding the epidemiology of medications use and the state of drug research in pregnancy, in an effort to highlight the need for pharmacologic research in pregnancy.
Assuntos
Aprovação de Drogas , Indústria Farmacêutica , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Gestantes , Medicamentos sob Prescrição/administração & dosagem , Adulto , Ensaios Clínicos como Assunto , Comorbidade , Relação Dose-Resposta a Droga , Aprovação de Drogas/legislação & jurisprudência , Indústria Farmacêutica/legislação & jurisprudência , Indústria Farmacêutica/organização & administração , Serviços de Informação sobre Medicamentos , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Recém-Nascido , Seleção de Pacientes , Polimedicação , Gravidez , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinética , Vigilância de Produtos Comercializados , Saúde da MulherRESUMO
Drug use and harms are increasingly common among newborns, infants, children, and adolescents during ambulatory practice, emergency department, and in-hospital treatment, including treatment in pediatric intensive care units. The pharmacokinetic and pharmacodynamic parameters of drugs often are different for children compared with adults and must be considered before prescribing. Drug exposure and the potential for harms also should be considered for fetuses and breastfeeding infants. As with adult patients, a thorough drug and allergy history (including nonprescription drugs and herbal and dietary supplements) should be obtained and reviewed at each medical visit. Children and adolescents are increasingly at risk of drug harm/overdose through accidental or intentional ingestion of nonprescription and prescription drugs (eg, cough and cold preparations, candy-appearing vitamins, stimulants, narcotics). Parents and caregivers should receive training in the proper use, storage, and administration of all drugs. Prescribing clinicians should be vigilant in withholding unnecessary drugs, such as antibiotics for viral infections. When prescribing, clinicians should be aware of common drugs frequently associated with adverse reactions, including stimulants, antipsychotics, analgesics, asthma therapies, acne therapies, and tumor necrosis factor inhibitors. Scientifically based prescribing practices should be used and consultation with evidence-based resources and pharmacists sought as needed.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Medicamentos sem Prescrição/farmacologia , Medicamentos sob Prescrição/farmacologia , Adolescente , Fatores Etários , Criança , Pré-Escolar , Interações Medicamentosas , Overdose de Drogas/prevenção & controle , Humanos , Prescrição Inadequada , Lactente , Recém-Nascido , Anamnese , Medicamentos sem Prescrição/efeitos adversos , Medicamentos sem Prescrição/farmacocinética , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinética , Fatores de RiscoRESUMO
The US Food and Drug Administration (FDA) draft guidance for industry on drug interaction studies recommends, but does not mandate, that both cigarette smokers and non-smokers can be used to study drug metabolism in clinical trials, and that important results related to smoking should be included in drug labelling to guide medication usage. This study aimed to provide a comprehensive review of drugs or diseases interacting with smoking, as presented in all US drug labelling. The 62,857 drug labels deposited in the FDA Online Label Repository were searched using the keywords 'smoke', 'smoker(s)', 'smoking', 'tobacco' and 'cigarette(s)' on 19 June 2014. The resultant records were refined to include only human prescription drug labelling, for manual examination. For 188 single-active-ingredient drugs and 36 multiple-active-ingredient drugs, the labelling was found to contain smoking-related information. The pharmacokinetics of 29 and 21 single-active-ingredient drugs were affected and unaffected, respectively, by smoking. For the remaining drugs, the provided information related to smoking affecting efficacy, safety or diseases but not pharmacokinetics. Depending on the nature of specific drugs, the perturbation in pharmacokinetic parameters in smokers ranged from 13 to 500%, in comparison with non-smokers. Dosage modifications in smokers are necessary for four drugs and may be necessary for six drugs, but are unnecessary for seven drugs although the pharmacokinetic parameters of four of them are affected by smoking. Cigarette smoking is a risk factor for 16 types of diseases or adverse drug reactions. For one single-active-ingredient contraceptive drug and 10 multiple-active-ingredient contraceptive drugs, a black box warning (the FDA's strongest safety warning) is included in the labelling for increased risks of heart attacks and strokes in female smokers, and "women are strongly advised not to smoke" when using these drugs. This study presents the first comprehensive overview of cigarette smoking interacting with drugs and/or diseases, as presented in US drug labelling.
Assuntos
Rotulagem de Medicamentos/normas , Medicamentos sob Prescrição/farmacocinética , Fumar/efeitos adversos , Fumar/metabolismo , Fatores Etários , Relação Dose-Resposta a Droga , Interações Medicamentosas , Humanos , Abandono do Hábito de Fumar/métodos , Estados Unidos , United States Food and Drug AdministrationRESUMO
This article reviews the necessary skills required for clinicians to make informed decisions about the use of medications in breastfeeding women. Even without specific data on certain medications, this review of kinetic principles, mechanisms of medication entry into breast milk, and important infant factors can aid in clinical decision making. In addition, the article reviews common medical conditions (eg, depression, hypertension, infections) in breastfeeding women and their appropriate treatment.
Assuntos
Aleitamento Materno , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Drogas Ilícitas/farmacocinética , Leite Humano/química , Medicamentos sob Prescrição/farmacocinética , Cafeína/farmacocinética , Cotinina/farmacocinética , Etanol/farmacocinética , Feminino , Humanos , Lactente , Recém-Nascido , Nicotina/farmacocinética , Medição de Risco , Estados UnidosRESUMO
Elderly patients are the most important target group of pharmacotherapy. Older individuals often suffer from multiple co-morbidities, which often results in polypharmacy. A therapy based on guidelines can be problematic and is only rarely examined in clinical trials of elderly patients. In addition, alterations in pharmacokinetics and pharmacodynamics due to increased age have to be considered. As a result of these changes, the elderly are particularly vulnerable to certain drugs. These drugs are classified as potentially inappropriate medication (PIM) for the elderly because they bear an increased risk of adverse drug events resulting in major safety concerns. Several classifications have been published to identify and avoid PIM. In this article, START/STOPP (Screening Tool to Alert doctors to Right Treatment/Screening Tool of Older Persons' potentially inappropriate Prescriptions), PRISCUS (Latin: time-honoured) as well as the Austrian PIM-list and FORTA (fit for the aged) criteria are discussed and explained in detail. The use of these tools is considered to be potentially useful in improving the quality of drug therapy for elderly people. Further, a regular medication review is recommended. The determination of the renal function, which is often limited in the elderly, resulting in a required dose adjustment of the medication as well as the choice of a low initial dose when starting a new drug in the elderly may also contribute to increased medication safety.
Assuntos
Quimioterapia Combinada/normas , Geriatria/normas , Erros de Medicação/prevenção & controle , Padrões de Prática Médica/normas , Idoso , Interações Medicamentosas , Alemanha , Fidelidade a Diretrizes/normas , Humanos , Prescrição Inadequada , Reconciliação de Medicamentos , Taxa de Depuração Metabólica/fisiologia , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinéticaRESUMO
Drug-drug interactions (DDI) are a major topic in programs for continuous medical education (CME). Many physicians are afraid of being trapped into charges of malpractice; however, DDI cannot be avoided in many cases. They belong to routine medical practice and it is often impossible to avoid them. Moreover, they do not just occur between drugs but between any kind of foreign substance (xenobiotica), such as food (e.g. grapefruit juice, broccoli, barbecue) as well as legal (e.g. tobacco smoke, caffeine and alcohol) and illegal drugs. Therefore, the medical challenge is not just to avoid any interaction. Instead the physician faces the question of how to proceed with drug treatment in the presence of such interactions. Based on the medical education a physician has to judge first of all whether there is a risk for interactions in the prescription being planned for an individual patient. The classification of interactions proposed in this article (PD1-PD4, PK1-PK3) might help as a sort of check list. For more detailed information the physician can then consult one of the many databases available on the internet, such as PSIAConline (http://www.psiac.de) and MediQ (http://www.mediq.ch). Pharmacokinetic interactions can be easily assessed, monitored and controlled by therapeutic drug monitoring (TDM). Besides these tools it is important to keep in mind that nobody knows everything; even physicians do not know everything. So take pride in asking someone who might help and for this purpose AGATE offers a drug information service AID (http://www.amuep-agate.de). Just good for nothing, without being based on any kind of medical approach are computer programs that judge prescriptions without taking into account a patient's individual peculiarities. In case these types of programs produce red exclamation marks or traffic lights to underline their judgment, they might even work in a contrapuntal way by just eliciting insecurity and fear.
Assuntos
Interações Medicamentosas , Medicamentos sob Prescrição/efeitos adversos , Xenobióticos/efeitos adversos , Antipsicóticos/efeitos adversos , Antipsicóticos/farmacocinética , Benzodiazepinas/efeitos adversos , Benzodiazepinas/farmacocinética , Biotransformação , Lista de Checagem , Comorbidade , Relação Dose-Resposta a Droga , Serviços de Informação sobre Medicamentos , Monitoramento de Medicamentos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Interações Alimento-Droga , Humanos , Inativação Metabólica , Taxa de Depuração Metabólica/fisiologia , Polimedicação , Medicamentos sob Prescrição/farmacocinética , Transtornos Relacionados ao Uso de Substâncias/sangue , Xenobióticos/farmacocinéticaRESUMO
A significant proportion of the elderly population is affected by multimorbidity and polypharmacy. Drug safety in this population is characterised by age-associated changes in pharmacokinetics and pharmacodynamics, an increased risk for drug-drug interactions, an unmanageable situation of side effects and co-morbidities, and a questionable adherence to complex therapies. Moreover, elderly multimorbid patients are usually not enrolled in clinical trials, and therefore the evidence for efficacy and safety of drugs is sparse. Many practice guidelines do not consider multimorbidity and age-associated changes in physical function, cognition and reduced life expectancy. Most published approaches to reducing polypharmacy such as algorithms and checklists have not yet been validated prospectively in randomised, controlled trials. However, some studies have shown the feasibility of stopping medications, in some cases accompanied by remarkable improvements of quality of life. (As supplied by publisher).
Assuntos
Doença Crônica/tratamento farmacológico , Quimioterapia Combinada/efeitos adversos , Serviços de Saúde para Idosos/organização & administração , Medicamentos sob Prescrição/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Comorbidade , Estudos de Viabilidade , Feminino , Alemanha , Humanos , Expectativa de Vida , Masculino , Adesão à Medicação , Guias de Prática Clínica como Assunto , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinética , Resultado do Tratamento , Suspensão de TratamentoAssuntos
Medicina Geral , Falência Renal Crônica/diagnóstico , Testes de Função Renal/métodos , Creatinina/sangue , Cistatina C/sangue , Alemanha , Taxa de Filtração Glomerular/fisiologia , Humanos , Inulina , Falência Renal Crônica/sangue , Valor Preditivo dos Testes , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinéticaRESUMO
PURPOSE: While some people remain fit and active as they grow older, others experience complex problems: disease, dependency and disability. Frailty is a term used to describe this latter group, capturing differences in health status among older people. Many frail older people have multiple chronic co-morbidities and functional impairments and, according to guidelines for the management of individual conditions, should be prescribed long lists of medications. However, older people (particularly those who are frail) are often excluded from drug trials, and treatment decisions are therefore based on evidence extrapolated from more robust patient groups with fewer physiological deficits. The risk of adverse drug reactions (ADRs) increases with increasing patient frailty, and polypharmacy has negative consequences above and beyond the risks of individual drugs. Increasing numbers of medications are associated with a higher likelihood of non-adherence and a significantly greater risk of ADRs. Older people taking five or more medications are at higher risk of delirium and falls, independent of medication indications. METHODS: This is a short review of the different approaches to defining and measuring frailty. We summarise the factors contributing to ADRs in frail older people and describe the pharmacokinetic and pharmacodynamics changes associated with ageing and frailty. By considering goals of care for frail older people, we explore how the appropriateness of medication prescribing for older people could be improved. CONCLUSION: Since all physicians are likely to provide care for this group of vulnerable patients, understanding the concept of frailty may help to optimise medication prescribing for older people. The incorporation of frailty measures into future clinical studies of drug effects and pharmacokinetics is important if we are to improve medication use and guide drug doses for fit and frail older people.
Assuntos
Envelhecimento , Prescrições de Medicamentos , Idoso Fragilizado , Padrões de Prática Médica , Medicamentos sob Prescrição/uso terapêutico , Acidentes por Quedas , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Comorbidade , Delírio/induzido quimicamente , Interações Medicamentosas , Avaliação Geriátrica , Humanos , Prescrição Inadequada , Adesão à Medicação , Seleção de Pacientes , Polimedicação , Medicamentos sob Prescrição/efeitos adversos , Medicamentos sob Prescrição/farmacocinética , Medição de Risco , Fatores de RiscoRESUMO
For cell and tissue localization of drugs, receptor microscopic autoradiography is reviewed, including its development history, multiple testing, extensive applications and significant discoveries. This sensitive high-resolution imaging method is based on the use of radiolabeled compounds (esp. tagged with (3)H or (125)I), preservation through freezing of in vivo localization of tissue constituents, cutting thin frozen sections, and close contact with the recording nuclear emulsion. After extensive testing of the utility of this method, the distribution of radiolabeled compounds has been identified and characterized for estradiol, progestagens, adrenal steroids, thyroid hormone, ecdysteroids, vitamin D, retinoic acid, metabolic indicators glucose and 2-deoxyglucose, as well as extracellular space indicators. Target cells and associated tissues have been characterized with special stains, fluorescing compounds, or combined autoradiography-immunocytochemistry with antibodies to dopamine-beta-hydroxylase, GABA, enkephalin, specific receptor proteins, or other cellular products. Blood-brain barrier and brain entries via capillary endothelium, ependyma, or circumventricular recess organs have been visualized for (3)H-dexamethasone, (210)Pb lead, and (3)H-1,25(OH)(2) vitamin D(3). With this histopharmacologic approach, cellular details and tissue integrative overviews can be assessed in the same preparation. As a result, information has been gained that would have been difficult or impossible otherwise. Maps of brain drug distribution have been developed and relevant target circuits have been recognized. Examples include the stria terminalis that links septal-amygdaloid-thalamic-hypothalamic structures and telencephalic limbic system components which extend as the periventricular autonomic-neuroendocrine ABC (Allocortex-Brainstem-Circuitry) system into the mid- and hindbrain. Discoveries with radiolabeled substances challenged existing paradigms, engendering new concepts and providing seminal incentives for further research toward understanding drug actions. Most notable are discoveries made during the 1980s with vitamin D in the brain together with over 50 target tissues that challenged the century-old doctrine of vitamin D's main role as 'the calcitropic hormone', when the new data made it apparent that the main biological function of this multifunctional sunshine hormone rather is maintenance of life and adapting vital functions to the solar environment. In the brain, vitamin D, in close relation to sex and adrenal steroids, participates in the regulation of the secretion of neuro-endocrines, such as, serotonin, dopamine, nerve growth factor, acetyl choline, with importance in prophylaxis and therapy of neuro-psychiatric disorders. Histochemical imaging with high cellular-subcellular resolution is necessary for obtaining detailed information, as this review indicates. New spectrometric methods, like MALDI-MSI, are unlikely to furnish the same information as receptor microautoradiography does, but can provide important correlative molecular information.